Satiasolv is a product containing cannabidiol, an active phytocannabinoid derived of Cannabis sativa. It is one of at least 85 active cannabinoids identified in the plant.
CBD interacts with the body‘s endocannabinoid system (ECS), which plays a key role in regulating sleep, mood, pain sensation, inflammation, and immune responses.
Solubility of highly active compounds is the key factor for efficient medical use. CBD is a hardly soluble and highly lipophilic API, classified as BCS class II drug of the Biopharmaceutics Classification System. Based on the proprietary Marinosolv® solubilizazion technology, Satiasolv allows for previously unavailable dosage options.
The permeation profile in a GIT-PAMPA assay revealed a higher permeation with a 100-times lower CBD concentration compared to a marketed state-of-the-art oil-based formulation, indicating an increased permeation of Marinosolv®-enabled cannabidiol, suggesting enhanced bioavailability and higher efficiency in physiological conditions mimicking the gastrointestinal tract when provided as a Marinosolv® formulation.
